Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM).

Full DD Report for BLCM

You must become a subscriber to view this report.


Recent News from (NASDAQ: BLCM)

Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association
HOUSTON, May 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that two abstracts on its lead product candidate BPX-501 have be...
Source: GlobeNewswire
Date: May, 17 2018 09:19
Bellicum Pharmaceuticals: Will This CAR-TCR Innovator Deliver Robust Profits?
Bellicum Pharmaceuticals (NASDAQ: BLCM ) is a stellar therapeutic innovator that has experienced a share price depreciation for the past year. Nevertheless, the company is powering the robust development of a highly advanced chimeric antigen receptor and T-cell receptor (CAR-TCR) that, in an...
Source: SeekingAlpha
Date: May, 16 2018 06:55
Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
HOUSTON, May 15, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that data from preclinical studies of its HER2-targeted CAR-T ce...
Source: GlobeNewswire
Date: May, 15 2018 07:00
Today's Research Reports on Stocks to Watch: OPKO Health and Bellicum Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / May 10, 2018 / Both OPKO Health and Bellicum Pharmaceuticals were flying high in the green on Wednesday after announcing first quarter results. Traders were enthusiastic over OPKO's Rayladee performance in the first quarter. RDI Initiates Coverage on: OPKO H...
Source: ACCESSWIRE IA
Date: May, 10 2018 08:20
Bellicum Pharmaceuticals beats by $0.01, beats on revenue
Bellicum Pharmaceuticals (NASDAQ: BLCM ): Q1 EPS of -$0.68 beats by $0.01 . More news on: Bellicum Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 17:04
Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results
HOUSTON, May 08, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter ended March 31, 2018...
Source: GlobeNewswire
Date: May, 08 2018 16:01
Bellicum prices offering at $7.50/share
Bellicum Pharmaceuticals (NASDAQ: BLCM ) has priced an upsized 8M-share offering at $7.50 each. More news on: Bellicum Pharmaceuticals, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: April, 17 2018 18:33
Midday Gainers / Losers (04/17/2018)
Gainers: CNET +42% . WMLP +21% . CIFS +21% . CLXT +20% . IIN +19% . NVLN +15% . IFON +15% . DPW +14% . CHEK +14% . GTHX +14% . More news on: ChinaNet Online Holdings, Inc., Westmoreland Resource Partners, LP, China Internet Nationwide Financial Services Inc...
Source: SeekingAlpha
Date: April, 17 2018 12:40
Premarket Losers as of 9:05 am (4/17/2018)
LADR -9% . More news on: Ladder Capital Corp, Bellicum Pharmaceuticals, Anavex Life Sciences Corp., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 17 2018 09:10
Bellicum Pharmaceuticals -6.9% on 7M-share public offering
Bellicum Pharmaceuticals (NASDAQ: BLCM ) -- a big gainer last Wednesday as the FDA lifted a clinical hold -- is 6.9% lower in postmarket action after announcing a 7M-share public offering . More news on: Bellicum Pharmaceuticals, Healthcare stocks news, Stocks on the move, Read mo...
Source: SeekingAlpha
Date: April, 16 2018 19:07

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-258.008.008.097.91475,683
2018-05-247.918.038.107.78348,016
2018-05-237.857.958.087.85462,775
2018-05-227.787.888.007.68361,272
2018-05-218.047.718.107.68573,977

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2575,082157,57447.6487Short
2018-05-2460,380133,50645.2264Short
2018-05-2393,868227,68241.2277Short
2018-05-2287,541154,76356.5646Short
2018-05-21141,154296,19147.6564Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BLCM.


About Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM)

Logo for Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: BLCM)

      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: April, 18 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 18 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 16 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: April, 16 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 13 2018

       

       


      Daily Technical Chart for (NASDAQ: BLCM)

      Daily Technical Chart for (NASDAQ: BLCM)


      Stay tuned for daily updates and more on (NASDAQ: BLCM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: BLCM)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BLCM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BLCM and does not buy, sell, or trade any shares of BLCM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/